The Effect of Cisplatin on Kidney Uptake of Technetium-99m-MDP in Rats

Abstract

Objective: The following experiments were performed to study the effect of cisplatin on the uptake of ^99mTc-MDP in kidneys. There is renal accumulation of ^99mTc-MDP bone imaging agents in patients treated with cisplatin.

Methods: Donryu rats weighing 150–160 g were administered 0.8 mg/kg of cisplatin intravenously for 7 days. On the day following the cisplatin injections and on the 37th day, we obtained ^99mTc-MDP clearance from the blood and it showed two components: a fast and a slow component.

Results: On both the first and 37th days, the fast component of the cisplatin-treated group was identical to the control rats. On the contrary, the slow component of the cisplatin-treated group and control rats was 393.6 ± 116.4 min and 85.2 ± 19.9 min, (p < 0.001), respectively. On the 37th day, the slow components in both groups were not significantly different. Technetium-99m-MDP bone scanning was performed on the first, 15th and 37th days following cisplatin administration. The scintigram on the first day showed high uptake ^99mTc-MDP in kidneys, bones and liver. On the 15th day, relatively high uptake in kidneys was observed. However, on the 37th day, ^99mTc-MDP uptake of the kidneys returned to normal. The binding rate of ^99mTc-MDP and ^99mTc-MDP with cisplatin were 99.4 ± 0.6% and 79.0 ± 4.6%, respectively.

Conclusion: This study suggested that high renal uptake of ^99mTc-MDP following administration of cisplatin was mainly due to delayed excretion of the radiopharmaceutical by binding with cisplatin.